Beverly Hills, California — October 3, 2025 — Leads & Copy — Nordicus Partners Corporation (OTCQB: NORD) has announced the formation of a new company, NoviThera Aps, to research and develop a novel Monoclonal antibody (MaB) therapy for psoriasis. Psoriasis, an immune-mediated inflammatory disease, causes keratinocyte hyperproliferation and inflammation, typically treated with topical creams, phototherapy, or interleukin antibodies.
NoviThera aims to develop a Monoclonal antibody treatment that may cure psoriasis or prevent its occurrence. The invention was made by Alteral Therapeutics in Denmark, with drug development acquired by NoviThera. Allan Wehnert will serve as CEO of NoviThera, focusing on developing a human rat model to selectively express pathological peptides and test them in relevant animal disease models.
Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. The company provides corporate finance activities, including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired Orocidin A/S and Bio-Convert A/S.
Mr. Henrik Rouf, Chief Executive Officer, hr@nordicuspartners.com, Tel +1 310 666 0750
Ulveman G Børsting, media inquiries, kontakt@ulvemanborsting.com
Source: Nordicus Partners Corporation
